Review Article
Peripheral Nerve Repair with Cultured Schwann Cells: Getting Closer to the Clinics

Maria Carolina O. Rodrigues,1,2 Antonio Antunes Rodrigues Jr.,1,3 Loren E. Glover,1 Julio Voltarelli,2 and Cesario V. Borlongan1

1 Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612, USA
2 Department of Internal Medicine, Faculty of Medicine of Ribeirão Preto, University of São Paulo, 14000 Ribeirão Preto, SP, Brazil
3 Department of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of São Paulo, 14000 Ribeirão Preto, SP, Brazil

Correspondence should be addressed to Cesario V. Borlongan, cborlong@health.usf.edu
Received 9 January 2012; Accepted 26 January 2012

Peripheral nerve injuries are a frequent and disabling condition, which affects 13 to 23 per 100,000 persons each year. Severe cases, with structural disruption of the nerve, are associated with poor functional recovery. The experimental treatment using nerve grafts to replace damaged or shortened axons is limited by technical difficulties, invasiveness, and mediocre results. Other therapeutic choices include the adjunctive application of cultured Schwann cells and nerve conduits to guide axonal growth. The bone marrow is a rich source of mesenchymal cells, which can be differentiated in vitro into Schwann cells and subsequently engrafted into the damaged nerve. Alternatively, undifferentiated bone marrow mesenchymal cells can be associated with nerve conduits and afterward transplanted. Experimental studies provide evidence of functional, histological, and electromyographical improvement following transplantation of bone-marrow-derived cells in animal models of peripheral nerve injury. This paper focuses on this new therapeutic approach highlighting its direct translational and clinical utility in promoting regeneration of not only acute but perhaps also chronic cases of peripheral nerve damage.

1. Introduction

The incidence of peripheral nerve injury in developed countries is estimated between 13 and 23 per 100,000 persons per year [1–3]. Common reported causes include motor vehicle accidents, lacerations with blades, glass or long bone fractures, and sports injuries. These statistics may be underestimated since only traumatic injuries that reach the health care system are included. Nontraumatic injuries, nerve damage secondary to abdominal or pelvic surgeries, and lesions that are not treated at a health facility remain to be accounted [3]. As an example, erectile dysfunction secondary to prostate surgeries associated with iatrogenic transection of erectile nerves occurs in approximately 35 to 86% of radical prostatectomy surgeries [4, 5]. It is, however, in the war scenario where the problem is more frequent. Blast injuries predominate, often associated with complex soft tissue and arterial wounds, most of which requiring limb amputation [6].

Peripheral nerve injuries are classified according to their severity, from type I, limited to demyelination, through type V, which comprises disruption of all three layers of the nerve endoneurium, perineurium, and epineurium. A sixth type of injury has also been described, with different degrees of lesion within individual fascicles from the same nerve [6]. Recovery is inversely proportional to the severity of damage. Endogenous repair initiates after injury but usually does not sustain itself beyond 12 months [7]. If the nerve does not heal within this period of time, recovery is unlikely and chronic pain and disability may persist. In serious injuries, surgical intervention is usually necessary, aiming to align the damaged axonal stumps, either through end-to-end sutures...
or by interposition of a nerve graft or even a scaffold for axonal growth. Frequently, however, the procedure does not suffice, and functional recovery is suboptimal [2, 6, 7].

Nerve repair is often disappointing and, despite best efforts, full functional recovery is seldom achieved, especially regarding motor nerves [2]. The high incidence of peripheral nerve damage, associated with poor reparative outcomes, indicates the importance of the problem and the demand for better regenerative therapies. In this context, the development of new approaches, including cell-based therapies, may improve outcomes and diminish the resulting disability of affected victims. Indeed, preclinical ongoing studies already show positive results in models of erectile, facial, optic, and sciatic nerve injuries [5, 8–11].

2. The Healing Process That Follows Nerve Injury

Peripheral nerve injury is followed by responses both from segments of the axon, proximal, and distal to the damaged area, and from the surrounding neural and nonneural cells. As a first endogenous reparative attempt, the neuronal cell body increases in size, the Nissl bodies dissolve, and the axon fragments, as the first stage of Wallerian degeneration. Interestingly, distal nerve disintegration does not start immediately upon injury. In primates, axons remain intact during days and can still transmit electric potentials when stimulated [13, 14]. The following fragmentation of the axon is a rapid event and seems to be mediated by activated intrinsic proteases, including calpain and the ubiquitin-protease system [12]. The distal detached nerve undergoes intrinsic fragmentation, as the first stage of Wallerian degeneration. The resulting supportive environment yields Schwann cell proliferation, formation of Büngner bands, and, finally, axonal sprouting [2, 26, 27]. This sprouting occurs at a rate of 1 to 4 mm per day, with progressive myelination of the fibers by the neighboring Schwann cells. The final repaired nerve usually presents thinner myelin sheets with shorter nodal lengths, less functional than the original nerve [28]. Time is an important factor affecting nerve repair. The supportive response mediated by neural and nonneural cells is more pronounced in the few months that follow nerve injury [6, 7, 28, 29]. When surgical intervention is delayed, the chronically denervated Schwann cells begin spontaneous apoptosis and repair becomes less probable. Recently, Gordon et al. demonstrated that although denervation of the distal stump is the main determinant, the denervated muscle also negatively impacts functional outcome [29]. Therefore, attempts to enhance nerve regeneration should be initiated as early as possible.

3. Interventions to Improve Peripheral Nerve Repair

Nerve repair requires a complex interaction of a scaffold for axonal proliferation, supportive cells such as the Schwann cells, growth factors, and extracellular matrix [2, 30]. Therefore, alignment of the nerve stumps stands as one of the first interventions after peripheral nerve injury. When end-to-end suture of the nerve is not possible, the interposition of a nerve conduit becomes necessary. Autologous grafts are often harvested from the sural or sensory nerves; however, sometimes there are limitations such as tissue availability, size incompatibilities, and deformities. Nevertheless, autologous nerve grafts are considered the gold standard for repairing peripheral nerve gaps [31]. Less frequently, allografts can be used, with the disadvantages of requiring immunosuppression and of producing worse outcomes than autografts.

More recently, tissue engineering has provided nerve conduits, which function as guides for axonal growth. Depending on the materials used for their construction, they can be classified as natural, when based on laminin, collagen or even vessels and decellularized nerves, or artificial, usually made of polymers. Artificial, nonbiodegradable scaffolds
aid nerve growth and provide beneficial results. However, these conduits may lead to chronic inflammation and tissue compression and therefore must be surgically removed once neural healing has been concluded. To avoid the hurdles of a second surgery on the injury site, biodegradable scaffolds are preferred. Table 1 includes some examples of experimental studies that used biodegradable scaffolds. Concerning humans, recently Åberg et al. suggested that wrapping-around injured wrist/forearm nerves with a resorbable poly[(R)-3-hydroxybutyrate] (PHB) implant, promoted significant sensory and motor improvements when compared to end-to-end epineural suture alone [32]. Importantly, no adverse effects were associated with the procedure, therefore considered safe.

Sensory nerves usually have better outcomes than motor nerves, after reconstructive interventions [48]. However, sensory repair is only warranted in areas of critical sensation, while motor nerves are usually indispensable. Motor nerve repair is mostly worth when the site of injury is close to the end organ because if the length to be repaired is too long, by the time reinnervation is achieved, the end-organ may be already unresponsive. In these cases, nerve transfer procedures, if available, may be attractive alternatives.

The major limitation for use of nerve conduits is the low rate of axonal growth, which may not yield full repair within the available time. Studies have shown that the conduits are effective in promoting repair of nerve gaps measuring up to 3 cm, while nerve autografts are required for bridging of larger distances [49, 50]. As an attempt to apply nerve guides for axonal growth in larger nerve injuries, Kokai et al. used polymer tube-like scaffolds associated with microparticles of GDNF, aiming to increase the rate of axonal growth and improve the success of functional restoration [40]. Endogenous Schwann cells have been shown to be attracted by the GDNF particles, increasing the rate of nerve regeneration. Similarly, Liu et al. observed higher nerve repair rates in rats with peripheral nerve injury treated with biodegradable conduits associated with nerve growth factor (NGF) [51].

Schwann cells are also potentiated by associations with other cell types or by bioengineering. Olfactory ensheathing cells (OECs) successfully repair peripheral nerve injuries and with less efficiency central nervous system axonal lesions [52]. However, Verdú et al. and You et al. demonstrated that the association of Schwann cells and OECs promotes better myelination and functional repair to injured sciatic axons than either cell type alone [53, 54]. Another studied approach involves genetic engineering, inducing the Schwann cells to express cell adhesion molecules, therefore improving their regenerative capacity. Increasing the rate of axonal repair may enhance the chances of successful functional recovery since the outcomes are in most cases time dependent. Lavdas et al. have investigated the effects of Schwann cells genetically modified to overexpress cell adhesion molecules, mostly the polysialylated form of neural cell adhesion molecule NCAM, on nervous system repair [55, 56]. It is hypothesized that these adhesion molecules improve transplanted cell migration, increasing their interaction with the host environment, therefore promoting more efficient functional integration. Additionally, cell adhesion molecules also stimulate axonal growth and remyelination, increasing the rate of renervation [57, 58].

4. Sources of Schwann Cells and Experimental Studies

Schwann cells are embryologically derived from the neural crest [59, 60]. Some neural crest pluripotent and stem cells (NCSCs) persist in adult specimens in sites of gliogenesis such as the sciatic nerve and dorsal root ganglia. Migration, proliferation, expression of growth factors, and remyelination capacity are listed features associated with Schwann cells, indicating their stem cell behavior [61, 62]. Attempts to use Schwann cells expanded in culture for neural repair have been described in the literature for over two decades [62]. Recently, Hood et al. used artificial tubes filled with autologous Schwann cells to replace gaps between sciatic nerve stumps of rats, with reported functional recovery [63].

The combination of axonal scaffolds and transplanted Schwann cells provides adequate support for peripheral nerve repair and has been investigated in the experimental setting as a strategy to circumvent the limitations of surgical repair [34, 37, 45]. The cells can be delivered inside a hollow tube, seeded in a hydrogel and subsequently filled into the lumen of the conduit, or placed inside a conduit containing a supportive structure [30]. Most studies use the first type of delivery, but it may be associated with substantial cell loss [38, 43, 46, 63]. Improved outcomes have been obtained using the second [34, 37] and third [45] approaches, but these are more technically complicated and costly. Although successful, these procedures are limited by the high number of cells required for each intervention, potential injury to the donor nerve, and fibroblast contamination of the cultures [64]. Therefore, alternative sources of supportive cells have been researched.

The bone marrow may be an attractive source despite the large number of available tissues from which Schwann cells can be obtained. Bone marrow mesenchymal cells have been studied for years in the context of in vitro expansion and transplantation [65]. Their ease of access, abundance, and safety are important attributes, especially concerning clinical application. Mesenchymal stromal cells (MSCs) or bone marrow stromal cells are multipotent somatic stem cells, from a nonhematopoietic precursor anchored in bone marrow that can differentiate in mesodermal cell linages, neural phenotypes, and also into Schwann-like cells [47, 66]. When MSCs are placed in an appropriate culture media, they transdifferentiate into a glial cell phenotype that expresses S100, GFAP, and p75 [67, 68]. In vitro differentiated cells show promising results when associated with artificial conduits and acellular grafts, promoting axonal and functional recovery [39, 41, 67].

Table 1 describes several preclinical studies that evaluate the reparative effects of different kinds of cell therapy upon peripheral nerve damage. Besides nervous tissue and bone marrow, other alternative sources of cell are investigated, such as the adipose tissue and skin. The skin dermis is...
Table 1: Preclinical studies evaluating cell therapy for peripheral nerve repair.

| Study                | Injury type/animal model                        | Cellular type/factor                                | Major findings                                           |
|----------------------|------------------------------------------------|---------------------------------------------------|---------------------------------------------------------|
| McKenzie et al. [33] | Sciatic nerve crush injury in myelin-deficient mice | Skin-derived precursors differentiated into Schwann cells | Remyelination and functional recovery                   |
| Udina et al. [34]    | Sciatic nerve injury in mice (0.6 cm gap)       | Collagen guides seeded with allogeneic Schwann cells plus FK-506 | Successful regeneration and functional recovery         |
| Negishi et al. [11]  | Optic nerve injury in rats (transsection)       | Extracellular matrix Schwann cells and neurotrophins | Axonal regeneration of retinal ganglion cells           |
| Reid et al. [35]     | Sciatic nerve injury in rats (1.0 cm gap)       | Adipose-derived stem cells                         | Dorsal root ganglia protection from apoptosis           |
| di Summa et al. [36] | Sciatic nerve injury in rats (1.0 cm gap)       | Nerve fibrin conduits seeded with adipose-derived stem cells | Enhanced peripheral nerve repair                         |
| Evans et al. [37]    | Sciatic nerve injury in rats (1.2 cm gap)       | Biosynthetic conduits seeded with Schwann cells     | Increased nerve regeneration                            |
| Koshimune et al. [38]| Sciatic nerve injury in rats (1.2 cm gap)       | Bioabsorbable Schwann cell-coated conduits         | Axonal regeneration                                     |
| Ladak et al. [39]    | Sciatic nerve injury in rats (1.2 cm gap)       | Bone marrow MSCs differentiated into Schwann-like cells seeded in collagen conduits | Regeneration of sciatic motoneuron                      |
| Kokai et al. [40]    | Sciatic nerve injury in rats (1.5 cm gap)       | Scaffolds containing GDNF microparticles            | Increased rate of nerve regeneration; migration and proliferation of Schwann cells |
| Dezawa et al. [41]   | Sciatic nerve injury in rats (1.5 cm gap)       | Bone marrow MSCs differentiated into Schwann-like cells suspended in Matrigel injected into hollow fibers | Successful nerve regeneration and myelination           |
| Marchesi et al. [42] | Sciatic nerve injury in rats (1.6 cm gap)       | Guides filled with skin-derived stem cells         | Functional recovery and myelination                      |
| Ansselin et al. [43] | Sciatic nerve injury in rats (1.8 cm gap)       | Nerve guides filled with syngeneic Schwann cells   | Successful nerve regeneration conditional to number of cells implanted |
| May et al. [5]       | Cavernous nerves sections in rats (0.5 cm gap)  | Silicon tubes seeded with GDNF-transduced Schwann cells | Increased recovery of erectile function                 |
| Sun et al. [44]      | Facial nerve injury in rats (0.8 cm gap)        | Decellularized artery allografts with autologous adipose-derived stem cells | Nerve repair and functional recovery                     |
| Wang et al. [10]     | Facial nerve injury in rabbits (1.0 cm gap)     | Autologous vein graft filled with autologous MSCs differentiated into Schwann cells | Improvement of functional recovery and upregulated myelin mRNA |
| Cheng and Chen [45]  | Sciatic nerve injury in rabbits (2.0 cm gap)    | Polylactin scaffolds seeded with Schwann cells and coated with biomembranes | Successful nerve regeneration                           |
| Zhang et al. [46]    | Tibial nerve injury in rabbits (4.0 cm gap)     | Autogenous venous graft filled with Schwann cells  | Successful nerve regeneration and electromyographic improvement |
Table 1: Continued.

| Study              | Injury type/animal model | Cellular type/factor                                      | Major findings                                      |
|--------------------|--------------------------|----------------------------------------------------------|-----------------------------------------------------|
| Wakao et al. [47]  | Non-human primates ulnar nerve injury (2.0 cm gap) | Collagen guides seeded with bone marrow MSC-derived Schwann cells | Functional, histological, and electromyographical recovery |
| Hu et al. [31]     | Non-human primates ulnar nerve injury (4.0 cm gap) | Acellular allogeneic nerve grafts with autologous MSCs     | Structural and functional peripheral nerve repair    |

The studies are grouped by animal model, nerve type, and injury size, starting with mice, followed by rats, rabbits, and nonhuman primates. The table does not list all the available studies but describes the main publications.

Another investigated cell source and contains neural crest-related precursors skin precursor cells SKPCs that can differentiate into neural crest cell types in vitro, including those with characteristics of peripheral neurons and Schwann cells [33, 69]. Also, the bulge area of the hair and whisker follicles harbors NCSC that can differentiate into Schwann-like cells, becoming an accessible source of cells for repair. Both NCSC and SKPC have been used in experiments of peripheral nerve and spinal cord injuries with functional improvement after transplantation [33, 42, 70, 71].

Regarding the adipose tissue, Reid et al. showed that differentiated adipose-derived Schwann cells expressed a range of intrinsic neurotrophic factors [35, 72]. They also demonstrated that the incorporation of either adipocyte-derived or nerve-derived Schwann cells into the repair site significantly increased the expression of anti-apoptotic m-RNA of Bcl-2 and decreased proapoptotic m-RNA Bax and caspase-3 in dorsal root ganglia, therefore promoting a neuroprotective effect [72]. In a comparative study for sciatic nerve repair using a fibrin conduit seeded with different cell populations, primary Schwann cells showed better results over adipose and bone-marrow-derived mesenchymal stem cells; however, the two last cell types still showed better axonal regeneration than the control, nontreated group [36]. Adipose-tissue-derived Schwann cells have also been used in experimental models of facial palsy with positive results [44]. Sun et al. published a study in rats with lesions of facial nerve that presented functional and electrophysiological recovery of nerve injuries measuring 0.8 cm.

Neural stem cells directly transplanted in the site of peripheral nerve injury differentiate into Schwann-like cells, secrete neural growth factors, and improve nerve regeneration [8]. In addition, these cells can enhance compatibility between transplanted and surrounding tissue, decreasing the necessity of immunosuppressive agents. Moreover, the coculture and cotransplantation of neural stem cells with Schwann cells increase the differentiation of neural stem cells into neurons and improve functional recovery in models of spinal cord injury [73].

Recently, Wakao et al. used collagen nerve conduits filled with autologous bone marrow MSC differentiated in vitro into Schwann cells to promote repair of median nerve injuries in monkeys [47] (Table 1). Successful outcomes were reported, with functional, histological, and electromyographical improvements. Interestingly, Hu et al. demonstrated that allogeneic acellular nerves filled with autologous, but nondifferentiated, bone-marrow-derived MSC also promoted functional recovery when placed in ulnar nerve gaps of nonhuman primates [31]. The success rates were comparable to those from nerve autografts and autologous Schwann-cell-filled acellular nerves and better than controls, which received the acellular nerves not filled with cells. The similar outcomes of both studies raise the hypothesis that predifferentiation of MSC into Schwann cells may not be necessary to achieve repair. Moreover, a previous study had demonstrated that allogeneic Schwann cells locally transplanted into a rat model of spinal cord injury induced the infiltration of endogenous Schwann cells into the damaged site [74]. Although the observation should not be transposed to peripheral nerve injury, it suggests a paracrine, rather than replacement therapeutic effect. On the other hand, Sun et al. recently published a study in rats with facial nerve injuries treated with decellularized allogeneic arteries filled with adipose-tissue-derived Schwann cells, where transplanted cells survived in the graft over 8 weeks [75]. Studies establishing the exact fate of labeled Schwann cells are still needed. Although in vitro studies demonstrate differentiation of the MSC into different cell types, mainly of mesodermal lineage, in vivo studies fail to show convincing evidence of such event. It is possible that the MSCs promote healing effects mostly through paracrine action, inducing recruitment of neighboring host cells, modulation of local and perhaps systemic immune response, and improving cell survival, than through direct cell differentiation.

5. Clinical Trial of Nerve Grafts and Scaffolds

Clinical applications of cell therapy for peripheral nerve repair are rare. A clinical trial conducted by the University of Stanford used scaffolding tubes filled with longitudinal collagen fibers as guides for axonal growth [76]. Such tubes were occupied by autologous cultured Schwann cells and served as a replacement for nerve autografts, aiming to repair short and long gaps. Results were partially reported, including cell harvesting, expansion in culture, and assembly of cells and nerve conduits, but clinical outcomes have not yet been published [76]. Another proposed study (ClinicalTrials.gov identifier: NCT00953277), currently recruiting patients, intends to evaluate the effects of a commercial nerve scaffold on erectile function and continence after video laparoscopic radical prostate excision [77]. The surgery is associated with high incidence of erectile nerve transection and directly affects postoperative quality of life of the patients [4, 5]. According to advertisements, the product is derived
from human decellularized nerves and may stand as an “off the shelf” product, viable for three years in frozen storage [78]. The same company sponsors a comparative study between the above-mentioned commercial human-derived nerve scaffold and synthetic or biosynthetic hollow tubes to repair peripheral nerve gaps in the hand (ClinicalTrials.gov identifier: NCT00948025) [79]. Although not yet approached by these last two studies, cell application to the nerve conduits may be attempted in the future.

6. Practical Issues

Cell-based therapy associated with scaffolds is a promising branch of regenerative medicine. Nerve injuries are a frequent and disabling condition, affecting young and productive subjects, which may benefit from such procedures. The idea of using nerve conduits filled with bone-marrow mesenchymal cells may be an attractive alternative to more aggressive therapies. If successful, the treatment may lead to functional improvement, avoiding the hurdles of additional surgeries and use of immunosuppressive drugs. A hypothetical scenario would be a patient with a traumatic limb injury, including extensive and severe damage of a motor nerve, resulting in acute disability. There would be a nerve gap, precluding any attempt of direct nerve suture. The use of a nerve conduit filled with allogeneic bone marrow-derived MSCs would be proposed, as an alternative to the standard autologous nerve graft implant. The acute nature of the condition would require a readily available source of cells, and since MSCs are immunoprivileged, indicating poor alloimmune response and therefore delayed rejection, allogeneic sources would be ideal. The cells would be already isolated from donated bone marrow, expanded in culture without further manipulation, tested for safety and quality, cryopreserved and ready for clinical use. The necessary amount of cells would then be thawed and inserted into biodegradable nerve conduits, readily implanted between nerve stumps during microsurgery. The therapy would require no immunosuppression and sequential functional and electromyographical evaluations would determine the outcomes. Expected results would be axonal repair, remyelination, and progressive functional improvement, either through differentiation of the transplanted into Schwann-like cells or, most probably, through paracrine effects of the bone-marrow-derived MSCs on the proximal axonal stump and remaining endogenous Schwann cells, stimulating regeneration (see Figure 1).

Cell banking is a developing resource for repair in degenerative, inflammatory, and traumatic disorders. The rising number of cell banking companies reflects the increasing number of emergent therapeutic applications for cells derived from the bone marrow, cord blood, and multiple other tissues. Although the regenerative potential and the properties of the cells change slightly from tissue to tissue, the bone marrow still stands as a preferred source of hematopoietic and mesenchymal cells, due safety, easy harvesting, and previous clinical experience [65]. Allogeneic cell banking seems more logical as an “off the shelf” product, however investments in autologous cell preservation may be also interesting, as an insurance against future illnesses. Transplanted autologous MSCs may persist in the injury site longer because of absent immune rejection, therefore promoting long-lasting effects.

The application of MSCs is associated with some hurdles. The most obvious is cell viability after thawing and insertion into the conduit. Orthopedic reconstructive surgeries are often long-lasting and the exposure of the cells to a hostile environment may jeopardize their survival. Therefore, one approach would be to leave cell implantation as a final step of the surgery, immediately followed by closure of the incision. Perhaps, performance of the surgery by a skilled surgeon may be critical. Additional aggressions to the cells would be the presence of infection or any situation leading to an acidic or hypoxogenated environment. Therefore, these conditions must be strictly controlled before cell transplantation. A second concern is that MSCs may lead to abnormal, nonlinear nerve growth, due to aberrant stimulation of the sprouting axonal buds. Although the problem has been observed in nerves stimulated with growth factors [80], such behavior is not expected following MSC grafts. This potential problem may be prevented through use of good quality conduits, possibly containing an internal supportive structure, aiming to guide newly formed axons in the direction of the distal nerve stump. Third, the therapy may promote cell differentiation toward a nonexpected cell type. Malignancy is not reported as a usual consequence of MSC administrations, but it is possible that due to the local host conditions the cells differentiate into nonneural cell types. Another concern that may be discussed is the functional integration of the transplanted cells into the injured nerve [81], although repair of peripheral nerve is usually more successful than central nervous system injuries. Finally, some donor conditions may interfere with MSC cultures, such as advanced age, smoking, and diabetes [82, 83]. In these cases, autologous use may not be the best choice.

In summary, despite the reported therapeutic benefits of MSC therapy in experimental models of peripheral nerve injury, there remain translational hurdles that still need to be addressed before the realization of large clinical trials for this treatment. In the future, this form of cell therapy may aggregate more complex features, such as addition of trophic factors within the conduits, manipulation of the cells for expression of neurotrophic factors or even adhesion molecules. On the other hand, the procedure may remain simple and enable the investigation of therapeutic pathways, perhaps unveiling a specific substance that would be therapeutically active, therefore sparing the use of cells.

7. Conclusions

Spontaneous peripheral nerve repair is disappointing even after microsurgical intervention, especially concerning severe injuries. Resulting chronic pain and disability affects victims of all ages, including those in economically active phase of life [3]. The available treatment using nerve grafts is very limited and invasive, and new therapeutic options are required. Schwann cell cultures have demonstrated favorable results in the experimental setting; however, the ideal source
Figure 1: Stem cell with scaffold support in peripheral nerve injury. (a) Nerve injury with stem cell transplantation shows limited remyelination and axonal growth between the proximal and distal stumps. (b) Nerve injury with scaffolding devices can be fabricated to secrete neurotrophic factors aiming to enhance the regenerative process, but still the outcome results in limited remyelination and axonal growth between the proximal and distal stumps. (c) The combined use of stem cells and scaffolding promotes best results, allowing an improved substrate for cell-to-cell contact and increased concentrations of released neurotrophic factors. Additionally, transplanted stem cells may stimulate endogenous Schwann cells to proliferate at a higher rate, thus enhancing remyelination and axonal growth following peripheral nerve damage.

MSCs secrete trophic factors, stimulating neuron regeneration, and, possibly, contributing to a supportive environment [85].

Cultured cells, combined with adjunctive treatments such as axonal growth guides, may be a feasible approach for future clinical studies (see Figure 1). Severe injuries in which nerve grafts are not available may benefit from this strategy that may provide an extracellular substrate for the transplanted cells and spared host cells allowing a bridge for cellular integration and/or a cellular and molecular pathway for improved paracrine effects. Moreover, studies investigating the effects of these cells over situations of delayed surgical intervention and chronic axonal denervation have not been reported. The neurotropic effect of these cells, combined with a favorable effect over the surrounding environment, may prolong the time window for axonal regeneration and, perhaps, improve the rates of functional restoration even in chronic cases.

Acknowledgments
C. V. Borlongan is supported by NIH NINDS 1R01NS071956-01, James and Esther King Foundation
References

[1] M. Asplund, M. Nilsson, A. Jacobsson, and H. von Holst, “Incidence of traumatic peripheral nerve injuries and amputations in Sweden between 1998 and 2006,” Neuroepidemiology, vol. 32, no. 3, pp. 217–228, 2009.
[2] G. R. D. Evans, “Peripheral nerve injury: a review and approach to tissue engineered constructs,” The Anatomical Record, vol. 263, no. 4, pp. 396–404, 2001.
[3] C. A. Taylor, D. Braza, J. B. Rice, and T. Dillingham, “The incidence of peripheral nerve injury in extremity trauma,” American Journal of Physical Medicine & Rehabilitation, vol. 87, no. 5, pp. 381–385, 2008.
[4] S. D. Kundu, K. A. Roehl, S. E. Eggener, J. A. Antenor, M. Han, and W. J. Catalona, “Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies,” Journal of Urology, vol. 172, no. 6 I, pp. 2227–2231, 2004.
[5] F. May, K. Matiassek, M. Vroemen et al., “GDNF-transduced schwann cell grafts enhance regeneration of erectile nerves,” European Urology, vol. 54, no. 5, pp. 1179–1187, 2008.
[6] W. W. Campbell, “Evaluation and management of peripheral nerve injury,” Critical Care Medicine, vol. 25, no. 5, pp. 1765–1774, 2007.
[7] O. A. Sulaiman and T. Gordon, “Effects of short- and long-term Schwann cell denervation on peripheral nerve regeneration, myelination, and size,” GLIA, vol. 32, no. 3, pp. 234–246, 2000.
[8] M. M. Dong and T. H. Yi, “Stem cell and peripheral nerve injury and repair,” Facial Plastic Surgery, vol. 26, no. 5, pp. 421–427, 2010.
[9] L. N. Zhou, J. W. Zhang, J. C. Wang, W. L. Lei, X. L. Liu, and L. H. Zhou, “Bone marrow stromal and Schwann cells from adult rats can interact synergistically to aid in peripheral nerve repair even without intercellular contact in vitro,” Cellular Physiology and Biochemistry, vol. 27, pp. 565–574, 2011.
[10] X. Wang, E. Luo, Y. Li, and J. Hu, “Schwann-like mesenchymal stem cells within vein graft facilitate nerve facial regeneration and remyelination,” Brain Research, vol. 1383, pp. 71–80, 2011.
[11] H. Negishi, M. Dezawa, T. Oshitari, and E. Adachi-Usami, "Optic nerve regeneration within artificial Schwann cell graft in the adult rat," Brain Research Bulletin, vol. 55, no. 3, pp. 409–419, 2001.
[12] F. E. Perrin, S. Lacroix, M. Avilés-Triueros, and S. David, "Involvement of monocyte chemoattractant protein-1, macrophage inflammatory protein-1α and interleukin-1β Wallerian degeneration," Brain, vol. 128, no. 4, pp. 854–866, 2005.
[13] V. Chaudhry, J. D. Glass, and J. W. Griffin, "Wallerian degeneration in peripheral nerve disease," Neurologic clinics, vol. 10, no. 3, pp. 613–627, 1992.
[14] R. W. Gilliatt and R. J. Hjorth, "Nerve conduction during Wallerian degeneration in the baloon," Journal of Neurology Neurosurgery and Psychiatry, vol. 35, no. 3, pp. 335–341, 1972.
[15] E. Touma, S. Kato, K. Fukui, and T. Koike, "Calpain-mediated cleavage of collapsin response mediator protein(CRMP)-2 during neurite degeneration in mice," European Journal of Neuroscience, vol. 26, no. 12, pp. 3368–3381, 2007.
[16] Q. Zhai, J. Wang, A. Kim et al., “Involvement of the ubiquitin-proteasome system in the early stages of Wallerian degeneration,” Neuron, vol. 39, no. 2, pp. 217–225, 2003.
[17] B. Beirowski, R. Adalbert, D. Wagner et al., “The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves,” BMC Neuroscience, vol. 6, article 6, 2005.
[18] M. P. Coleman and M. R. Freeman, “Wallerian degeneration, WldS, and Nmnat,” Annual Review of Neuroscience, vol. 33, pp. 245–267, 2010.
[19] M. E. Vargas and B. A. Barres, “Why is Wallerian degeneration in the CNS so slow?” Annual Review of Neuroscience, vol. 30, pp. 153–179, 2007.
[20] S. David and S. Lacroix, “Molecular approaches to spinal cord repair,” Annual Review of Neuroscience, vol. 26, pp. 411–440, 2003.
[21] T. Gordon, “The role of neurotrophic factors in nerve regeneration,” Neurosurgical Focus, vol. 26, no. 2, article E3, 2009.
[22] S. Walsh and R. Midha, “Practical considerations concerning the use of stem cells for peripheral nerve repair,” Neurosurgical Focus, vol. 26, no. 2, p. E2, 2009.
[23] G. Vrbova, N. Mehra, H. Shanmuganathan, N. Tyrem, M. Schachner, and T. Gordon, “Chemical communication between regenerating motor axons and Schwann cells in the growth pathway,” European Journal of Neuroscience, vol. 30, no. 3, pp. 366–375, 2009.
[24] R. Martini, M. Schachner, and T. M. Brusht, “The L2/HNK-1 carbohydrate is preferentially expressed by previously motor axon-associated Schwann cells in reinervated peripheral nerves,” The Journal of Neuroscience, vol. 14, no. 11, pp. 7180–7191, 1994.
[25] S. Goethals, E. Ydens, V. Timmerman, and S. Janssens, “Toll-like receptor expression in the peripheral nerve,” GLIA, vol. 58, no. 14, pp. 1701–1709, 2010.
[26] G. Stoll, S. Jander, and R. R. Myers, “Degeneration and regeneration of the peripheral nervous system: from Augustus Waller’s observations to neuroinflammation,” Journal of the Peripheral Nervous System, vol. 7, no. 1, pp. 13–27, 2002.
[27] E. B. George, J. D. Glass, and J. W. Griffin, “Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels,” Journal of Neuroscience, vol. 15, no. 10, pp. 6445–6452, 1995.
[28] A. D. Gaudet, P. G. Popovich, and M. S. Ramer, “Wallerian degeneration: gaining perspective on inflammatory events after peripheral nerve injury,” Journal of Neuroinflammation, vol. 8, article 110, 2011.
[29] T. Gordon, N. Tyrem, and M. A. Raji, “The basis for diminished functional recovery after delayed peripheral nerve repair,” Journal of Neuroscience, vol. 31, no. 14, pp. 5325–5334, 2011.
[30] L. A. Pfister, M. Papaloizos, H. P. Merkle, and B. Gander, “Nerve conduits and growth factor delivery in peripheral nerve repair,” Journal of the Peripheral Nervous System, vol. 12, no. 2, pp. 65–82, 2007.
[31] J. Hu, Q. T. Zhu, X. L. Liu, Y. B. Xu, and J. K. Zhu, “Repair of extended peripheral nerve lesions in rhesus monkeys using acellular allogenic nerve grafts implanted with autologous mesenchymal stem cells,” Experimental Neurology, vol. 204, no. 2, pp. 658–666, 2007.
[32] M. Åberg, C. Ljungberg, E. Edin et al., “Clinical evaluation of a resorbable wrap-around implant as an alternative to nerve repair: a prospective, assesor-blinded, randomised clinical study of sensory, motor and functional recovery after peripheral nerve repair,” Journal of Plastic, Reconstructive and Aesthetic Surgery, vol. 62, no. 11, pp. 1503–1509, 2009.
[33] I. A. McKenzie, J. Biernaskie, J. G. Toma, R. Midha, and F. D. Miller, "Skin-derived precursors generate myelinating Schwann cells for the injured and dysmyelinated nervous system," *Journal of Neuroscience*, vol. 26, no. 24, pp. 6651–6660, 2006.

[34] E. Udina, F. J. Rodriguez, E. Verdú, M. Espejo, B. G. Gold, X. Navarro, "FK506 enhances regeneration of axons across long peripheral nerve gaps repaired with collagen guides seeded with allogeneic Schwann cells," *GLIA*, vol. 47, no. 2, pp. 120–129, 2004.

[35] A. J. Reid, M. Sun, M. Wiberg, S. Downes, G. Terenghi, and P. J. Kingham, "Nerve repair with adipose-derived stem cells protects dorsal root ganglia neurons from apoptosis," *Neuroscience*, vol. 199, pp. 515–522, 2011.

[36] P. G. di Summa, P. J. Kingham, W. Raffoul, M. Wiberg, G. Terenghi, and D. F. Kalbermatten, "Adipose-derived stem cells enhance peripheral nerve regeneration," *Journal of Plastic, Reconstructive and Aesthetic Surgery*, vol. 63, no. 9, pp. 1544–1552, 2010.

[37] G. R. Evans, K. Brandt, S. Katz et al., "Bioactive poly(L-lactic acid) conduits seeded with Schwann cells for peripheral nerve regeneration," *Biomaterials*, vol. 23, no. 3, pp. 841–848, 2002.

[38] M. Koshimune, K. Takamatsu, H. Nakatsuka, K. Inui, Y. Yamano, and Y. Ikada, "Creating bioabsorbable Schwann cell coated conduits through tissue engineering," *Bio-Medical Materials and Engineering*, vol. 13, no. 3, pp. 223–229, 2003.

[39] A. Ladak, J. Olson, E. E. Tredget, and T. Gordon, "Differentiation of mesenchymal stem cells to support peripheral nerve regeneration in a rat model," *Experimental Neurology*, vol. 228, no. 2, pp. 242–252, 2011.

[40] L. E. Kokal, A. M. Ghaznavi, and K. G. Marra, "Incorporation of double-walled nanospheres into polymer nerve guides for the sustained delivery of glial cell line-derived neurotrophic factor," *Biomaterials*, vol. 31, no. 8, pp. 2313–2322, 2010.

[41] M. Dezawa, I. Takahashi, M. Esaki, M. Takano, and H. Sawada, "Sciatic nerve regeneration in rats induced by transplantation of in vitro differentiated bone-marrow stromal cells," *European Journal of Neuroscience*, vol. 14, no. 11, pp. 1771–1776, 2001.

[42] C. Marchesi, M. Pluder, F. Colleoni et al., "Skin-derived stem cells transplanted into resorbable guides provide functional nerve regeneration after sciatic nerve resection," *GLIA*, vol. 55, no. 4, pp. 425–438, 2007.

[43] A. D. Asselin, T. Fink, and D. F. Davey, "Peripheral nerve regeneration through nerve guides seeded with adult Schwann cells," *Neuropathology and Applied Neurobiology*, vol. 23, no. 5, pp. 387–398, 1997.

[44] F. Sun, K. Zhou, J.-W. Mi, and J.-H. Qiu, "Repair of facial nerve defects with decellularized artery allografts containing autologous adipose-derived stem cells in a rat model," *Neuroscience Letters*, vol. 499, no. 2, pp. 104–108, 2011.

[45] B. Cheng and Z. Chen, "Fabricating autologous tissue to engineer artificial nerve," *Microsurgery*, vol. 22, no. 4, pp. 133–137, 2002.

[46] F. Zhang, B. Blain, J. Beck et al., "Autogenous venous graft with one-stage prepared Schwann cells as a conduit for repair of long segmental nerve defects," *Journal of Reconstructive Microsurgery*, vol. 18, no. 4, pp. 295–300, 2002.

[47] S. Wakao, T. Hayashi, M. Kitada et al., "Long-term observation of auto-cell transplantation in non-human primate reveals safety and efficiency of bone marrow stromal cell-derived Schwann cells in peripheral nerve regeneration," *Experimental Neurology*, vol. 223, no. 2, pp. 537–547, 2010.

[48] I. K. Fox and S. E. MacKinnon, "Adult peripheral nerve disorders: nerve entrapment, repair, transfer, and brachial plexus disorders," *Plastic and Reconstructive Surgery*, vol. 127, no. 5, pp. 105e–118e, 2011.

[49] B. Schlosshauer, L. Dreessen, H. E. Schaller, and N. Sinis, "Synthetic nerve guide implants in humans: a comprehensive survey," *Neurosurgery*, vol. 59, no. 4, pp. 740–747, 2006.

[50] Y. T. Kim, V. K. Hafelt, S. Kumar, and R. V. Bellamkonda, "The role of aligned polymer fiber-based constructs in the bridging of long peripheral nerve gaps," *Biomaterials*, vol. 29, no. 21, pp. 3117–3127, 2008.

[51] J. J. Liu, C. Y. Wang, J. G. Wang, H. J. Ruan, and C. Y. Fan, "Peripheral nerve regeneration using composite poly(lactic acid-caprolactone)/nerve growth factor conduits prepared by coaxial electrospinning," *Journal of Biomedical Materials Research A*, vol. 96, no. 1, pp. 13–20, 2011.

[52] C. Radtke, A. A. Aizer, S. K. Agulian, K. L. Lankford, P. M. Vogt, and J. D. Kocsis, "Transplantation of olfactory ensheathing cells enhances peripheral nerve regeneration after microsurgical nerve repair," *Brain Research*, vol. 1254, pp. 10–17, 2009.

[53] E. Verdú, X. Navarro, G. Gudiño-Cabrera et al., "Olfactory bulb ensheathing cells enhance peripheral nerve regeneration," *NeuroReport*, vol. 10, no. 5, pp. 1097–1101, 1999.

[54] H. You, L. Wei, Y. Liu et al., "Olfactory ensheathing cells enhance Schwann cell-mediated anatomical and functional repair after sciatic nerve injury in adult rats," *Experimental Neurology*, vol. 229, no. 1, pp. 158–167, 2011.

[55] A. A. Lavdas, I. Franceschini, M. Dubois-Dalcq, and R. Matsas, "Schwann cells genetically engineered to express PSA show enhanced migratory potential without impairment of their myelinating ability in vitro," *GLIA*, vol. 53, no. 8, pp. 868–878, 2006.

[56] F. Papastefanaki, J. Chen, A. A. Lavdas, D. Thomaidou, M. Schachner, and R. Matsas, "Grafts of Schwann cells engineered to express PSA-NCAM promote functional recovery after spinal cord injury," *Brain*, vol. 130, no. 8, pp. 2159–2174, 2007.

[57] D. Siu, "A new way of targeting to treat nerve injury," *International Journal of Neuroscience*, vol. 120, no. 1, pp. 1–10, 2010.

[58] Y. Zhang, J. Yeh, P. M. Richardson, and X. Bo, "Cell adhesion molecules of the immunoglobulin superfamily in axonal regeneration and neural repair," *Restorative Neurology and Neuroscience*, vol. 26, no. 2–3, pp. 81–96, 2008.

[59] N. M. Le Douarin and E. Dupin, "Multipotentiality of the neural crest," *Current Opinion in Genetics and Development*, vol. 13, no. 5, pp. 529–536, 2003.

[60] A. Woodhoo and L. Sommer, "Development of the Schwann cell lineage: from the neural crest to the myelinated nerve," *Glia*, vol. 56, no. 14, pp. 1481–1490, 2008.

[61] C. V. Borlongan, "Remyelinating the transected peripheral nerve by fabricated Schwann cells derived from bone marrow," *Experimental Neurology*, vol. 225, no. 2, pp. 243–245, 2010.

[62] I. D. Duncan, A. J. Aguayo, R. P. Bunge, and P. M. Wood, "Transplantation of rat Schwann cells grown in tissue culture into the mouse spinal cord," *Journal of the Neurological Sciences*, vol. 49, no. 2, pp. 241–252, 1981.

[63] B. Hood, H. B. Levene, and A. D. Levi, "Transplantation of autologous Schwann cells for the repair of segmental peripheral nerve defects," *Neurosurgical Focus*, vol. 26, no. 2, pp. E4, 2009.

[64] A. Niapour, F. Karamali, K. Karbalaie et al., "Novel method to obtain highly enriched cultures of adult rat Schwann cells," *Biomaterials*, vol. 32, no. 6, pp. 781–786, 2010.
[65] K. Le Blanc and O. Ringdén, “Immunomodulation by mesenchymal stem cells and clinical experience,” *Journal of Internal Medicine*, vol. 262, no. 5, pp. 509–525, 2007.

[66] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” *Science*, vol. 284, no. 5411, pp. 143–147, 1999.

[67] G. Keilhoff, K. Langnaese, G. Wolf, and H. Fansa, “Inhibiting effect of minocycline on the regeneration of peripheral nerves,” *Developmental Neurobiology*, vol. 67, no. 10, pp. 1382–1395, 2007.

[68] M. Tohill and G. Terenghi, “Stem-cell plasticity and therapy for injuries of the peripheral nervous system,” *Biotechnology and Applied Biochemistry*, vol. 40, no. 1, pp. 17–24, 2004.

[69] C. E. Wong, C. Paratore, M. T. Dours-Zimmermann et al., “Neural crest-derived cells with stem cell features can be traced back to multiple lineages in the adult skin,” *Journal of Cell Biology*, vol. 175, no. 6, pp. 1005–1015, 2006.

[70] Y. Amoh, L. Li, M. Yang et al., “Hair follicle-derived blood vessels vascularize tumors in skin and are inhibited by doxorubicin,” *Cancer Research*, vol. 65, no. 6, pp. 2337–2343, 2005.

[71] J. Biernaskie, J. S. Sparling, J. Liu et al., “Skin-derived precursors generate myelinating Schwann cells that promote remyelination and functional recovery after contusion spinal cord injury,” *Journal of Neuroscience*, vol. 27, no. 36, pp. 9545–9559, 2007.

[72] P. J. Kingham, D. F. Kalbermatten, D. Mahay, S. J. Armstrong, M. Wiberg, and G. Terenghi, “Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote neurite outgrowth in vitro,” *Experimental Neurology*, vol. 207, no. 2, pp. 267–274, 2007.

[73] A. Niapour, F. Karamali, S. Nemati et al., “Co-transplantation of human embryonic stem cell-derived neural progenitors and schwann cells in a rat spinal cord contusion injury model elicits a distinct neurogenesis and functional recovery,” *Cell Transplantation*. In press.

[74] C. E. Hill, L. D. Moon, P. M. Wood, and M. B. Bunge, “Labeled Schwann cell transplantation: cell loss, host Schwann cell replacement, and strategies to enhance survival,” *GLIA*, vol. 53, no. 3, pp. 338–343, 2006.

[75] F. Sun, K. Zhou, W.-J. Mi, and J.-H. Qiu, “Combined use of decellularized allogeneic artery conduits with autologous transdifferentiated adipose-derived stem cells for facial nerve regeneration in rats,” *Biomaterials*, vol. 32, no. 32, pp. 8118–8128, 2011.

[76] E. E. Sabelman and V. R. Hentz, “Clinical Trial of Peripheral Nerve Graft,” ClinicalTrials.gov. 1999.

[77] AxoGen, Inc., “Study of Nerve Reconstruction using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer,” ClinicalTrials.gov. 2011.

[78] AxoGen, Inc., “Avance Nerve Graft: The Natural Connection,” 2011, http://www.Axogeninc.com.

[79] AxoGen, Inc., “Study of Nerve Reconstruction using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer,” ClinicalTrials.gov. 2011.

[80] A. Blesch, H. S. Uy, R. J. Grill, J. G. Cheng, P. H. Patterson, and M. H. Tuszyński, “Leukemia inhibitory factor augments neurotrophin expression and corticospinal axon growth after adult CNS injury,” *Journal of Neuroscience*, vol. 19, no. 9, pp. 3556–3566, 1999.

[81] A. A. Lavdas, F. Papastefanaki, D. Thomaidou, and R. Matsas, “Schwann cell transplantation for CNS repair,” *Current Medicinal Chemistry*, vol. 15, no. 2, pp. 151–160, 2008.

[82] K. Tan, E. Lessieur, A. Cutler et al., “Impaired function of circulating CD34+ CD45− cells in patients with proliferative diabetic retinopathy,” *Experimental Eye Research*, vol. 91, no. 2, pp. 229–237, 2010.

[83] W. Wagner, S. Bork, P. Horn et al., “Aging and replicative senescence have related effects on human stem and progenitor cells,” *Plos ONE*, vol. 4, no. 6, Article ID e5846, 2009.

[84] J. Doorn, G. Moll, K. Le Blanc, C. van Blitterswijk, and J. De Boer, “Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements,” *Tissue Engineering B*, vol. 18, pp. 101–115, 2012.

[85] G. Moll, R. Jitschin, L. von Bahr et al., “Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses,” *Plos ONE*, vol. 6, no. 7, Article ID e21703, 2011.